Skip to main content
LH
NYSE Industrial Applications And Services

Labcorp Tops Q2 Estimates, Lifts Full-Year Outlook, and Boosts Buyback by $1B

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$307.05
Mkt Cap
$25.186B
52W Low
$244.52
52W High
$315.773
52W Position info
26% above low
Off High info
2.8% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

LH sits 26% above its 52-week low of $244.52.

Summary

Labcorp posted Q2 2026 revenue of $3.73 billion and adjusted EPS of $4.99, both above consensus, and raised full-year guidance. The board also approved a $1.0 billion increase in share repurchase authorization, bringing the total remaining to $1.4 billion.


Key Events · Earnings and Guidance · LH

  • Q2 Revenue and EPS Beat

    Revenue reached $3.73 billion, up 5.8% year-over-year, while adjusted EPS of $4.99 rose 14.9%, fueled by organic growth and margin expansion across both Diagnostics and Biopharma segments.

  • Raised Full-Year Guidance

    Reflecting a strong first half and an upbeat outlook, management lifted 2026 adjusted EPS guidance to $18.10–$18.55 (midpoint up $0.30) and revenue growth guidance to 5.4%–6.3% (midpoint up 30 bps).

  • $1.0B Buyback Authorization Increase

    The board approved a $1.0 billion increase in share repurchase authorization, bringing the total remaining to $1.4 billion. In Q2 alone, the company repurchased $353.8 million of stock.

  • Debt Reduction and Acquisitions

    Labcorp retired $500 million in senior notes in June and completed acquisitions of Parkview Health outreach lab services and Tribal Diagnostics, deploying $225.7 million in M&A during the quarter.


Analysis · LH · Industrial Applications And Services

A strong second quarter saw revenue climb 6% and adjusted EPS jump 15%, comfortably ahead of expectations. The raised full-year revenue and EPS guidance signals management's conviction in sustained momentum. Notably, the $1.0 billion increase in share repurchase authorization—lifting the total to $1.4 billion—represents a substantial capital return commitment that underscores management's view of the stock's value. With $353.8 million in buybacks executed during the quarter and $500 million in debt retired, the capital allocation actions are decidedly shareholder-friendly and support the stock near its 52-week high.

At the time of this filing, LH was trading at $307.05 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $25.2B. The 52-week trading range was $244.52 to $315.77. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LH - Latest Insights

LH
Jul 30, 2026, 6:50 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $307.05
Real-time Price: $290.00 info
Change: -$17.05 (-6%) info
Market Cap: $25.186B info
LH
Jul 28, 2026, 4:39 AM EDT
Source: dpa-AFX
Importance Score:
8
Price at Filing: $301.60
Real-time Price: $290.00 info
Change: -$11.60 (-4%) info
Market Cap: $25.186B info
LH
Jun 22, 2026, 7:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $255.82
Real-time Price: $290.00 info
Change: +$34.18 (+13%) info
Market Cap: $25.186B info
LH
Jun 08, 2026, 12:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $263.22
Real-time Price: $290.00 info
Change: +$26.78 (+10%) info
Market Cap: $25.186B info
LH
May 29, 2026, 7:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $262.75
Real-time Price: $290.00 info
Change: +$27.25 (+10%) info
Market Cap: $25.186B info